Drug Profile

BP 1210

Alternative Names: BP-1210

Latest Information Update: 01 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BrightPath Biotherapeutics
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

01 Jun 2022 Preclinical trials in Cancer in Japan (Parenteral), as of June 2022 (BrightPath Biotherapeutics pipeline, June 2022)
05 Oct 2021 BP 1210 is available for licensing as of 05 Oct 2021. https://www.brightpathbio.com
01 Oct 2021 Early research in Cancer in Japan (Parenteral) as of October 2021 (BrightPath Biotherapeutics pipeline; October 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com